ライフサイエンスコーパス: atrial natriuretic

1 CNP and (Cys18)-atrial natriuretic factor (4-23) amide (cANF(4-23)) elic

2 19%), secreted more apoB, and expressed less atrial natriuretic factor (ANF) and brain natriuretic pe

3 5 haploinsufficiency also markedly decreased atrial natriuretic factor (ANF) and connexin 40 (cx40) t

4 function, its synergism with partners at the atrial natriuretic factor (ANF) and connexin-40 (Cx40) p

5 are markers of cardiac hypertrophy including atrial natriuretic factor (ANF) and myosin light chain-2

6 (GSK3beta) is critical for transcription of atrial natriuretic factor (ANF) by beta-adrenergic recep

7 induced increases in NADPH oxidase activity, atrial natriuretic factor (ANF) expression, and cardiac

8 IL-18 has also been shown to induce atrial natriuretic factor (ANF) gene expression in adult

9 The atrial natriuretic factor (ANF) gene is initially expres

10 otic expression screen for activators of the atrial natriuretic factor (ANF) gene, a cardiac-specific

11 Atrial natriuretic factor (ANF) is abundantly expressed

12 In contrast, while MnTMPyP inhibited basal atrial natriuretic factor (ANF) mRNA expression, the str

13 ed protein content, [3H] leucine uptake, and atrial natriuretic factor (ANF) promoter activity.

14 containing c-Jun and with the cardiomyocyte atrial natriuretic factor (anf) promoter and the cardiac

15 We report here that the atrial natriuretic factor (ANF) promoter is a target of

16 vation of cardiac gene promoters such as the atrial natriuretic factor (ANF) promoter.

17 ignificance of this interaction, we used the atrial natriuretic factor (ANF) promoter.

18 bx20, activates a cardiac-specific promoter (atrial natriuretic factor (ANF)) alone and synergistical

19 embryonic hearts expressed similar levels of atrial natriuretic factor (ANF), brain natriuretic pepti

20 Zic3(null/y) embryonic stem cells including atrial natriuretic factor (ANF), Nkx2.5 and Tbx5.

21 perated with c-Raf to increase expression of atrial natriuretic factor (ANF), whereas N17Rac1 inhibit

22 We found that atrial natriuretic factor (ANF), which is normally expre

23 ion of cardiac-specific genes, including the atrial natriuretic factor (ANF).

24 We investigated the potential of a C-type atrial natriuretic factor (C-ANF) to image developing pl

25 ently, we reported the (64)Cu-labeled C-type atrial natriuretic factor (CANF) fragment for detecting

26 mg/mm; p<0.001) and reduced LV expression of atrial natriuretic factor (p<0.05), alpha-skeletal muscl

27 nduced expression of two hypertrophic genes (atrial natriuretic factor [ANF] and c-myc) and also enha

28 n neonatal hearts, ventricular expression of atrial natriuretic factor and alpha-skeletal actin was m

29 ificantly increased heart/body weight ratio, atrial natriuretic factor and beta-myosin heavy chain mR

30 e cross-sectional areas, hypertrophy markers atrial natriuretic factor and beta-myosin heavy chain).

31 ition, two cardiac hypertrophy marker genes, atrial natriuretic factor and beta-myosin heavy chain, w

32 en synthesis and hypertrophy markers such as atrial natriuretic factor and beta-myosin heavy chain.

33 enuated expression of the trabecular markers atrial natriuretic factor and bone morphogenic protein 1

34 el pathways associated with up-regulation of atrial natriuretic factor and brain natriuretic peptide

35 ist-induced expression of the embryonic gene atrial natriuretic factor and enlargement of cardiomyocy

36 f the expression of various genes, including atrial natriuretic factor and Ifi204 (encoding p204).

37 trophy, increased expression of fetal genes (atrial natriuretic factor and skeletal alpha-actin), dec

38 , overexpression of NF-kappaB itself induced atrial natriuretic factor expression and cardiomyocyte e

39 ment, sarcomeric organization, and increased atrial natriuretic factor expression in association with

40 Hypertrophy and atrial natriuretic factor expression induced by angioten

41 Atrial natriuretic factor expression was approximately 6

42 ction, which induced myocyte hypertrophy and atrial natriuretic factor expression, protected against

43 ficant reduction in NF-kappaB activation and atrial natriuretic factor expression.

44 ed protein synthesis, cell surface area, and atrial natriuretic factor expression.

45 In contrast, secretion of atrial natriuretic factor from ventricular myocytes was

46 ocardin A transactivated the promoter of the atrial natriuretic factor gene through the serum respons

47 ssion of cardiac-specific promoters from the atrial natriuretic factor gene, the b-type natriuretic p

48 n, whereas it did not increase expression of atrial natriuretic factor gene.

49 ithin the proximal promoter -242 site of the atrial natriuretic factor gene.

50 els of cardiac hypertrophy and expression of atrial natriuretic factor in Mekk1(-/-) animals, which s

51 s-sectional area, and hypertrophy-associated atrial natriuretic factor induction following pressure o

52 days) did not affect the trophic response or atrial natriuretic factor induction to pressure overload

53 c mass, myocyte size, hypertrophy-associated atrial natriuretic factor induction, and c-Jun N-termina

54 O mice shows a dramatic up-regulation of the atrial natriuretic factor message, a well-established bi

55 here were no significant changes in IGF-1 or atrial natriuretic factor mRNA levels in response to GH

56 - the natriuretic peptides - referred to as atrial natriuretic factor or atrial natriuretic peptide

57 Serum increased atrial natriuretic factor promoter activity and cell siz

58 We tested atrial natriuretic factor promoter activity as a positiv

59 as co-transfected with SRF, but it repressed atrial natriuretic factor promoter activity, which was s

60 P-TF2dependent synergistic activation of the atrial natriuretic factor promoter by both GATA4 and the

61 educed the capability of SRF to activate the atrial natriuretic factor promoter that contains the ser

62 hat Tip60 and SRF cooperatively activate the atrial natriuretic factor promoter.

63 onal responsiveness of ELK-1, GATA4, and the atrial natriuretic factor promoter.

64 novel VEGF-B167 transgene controlled by the atrial natriuretic factor promoter.

65 that TBX5 activates the transcription of an atrial natriuretic factor reporter construct and this ef

66 ing adult heart, steady-state mRNA levels of atrial natriuretic factor were increased in both the fet

67 ed in the morphants including an increase in atrial natriuretic factor, a hallmark for cardiac hypert

68 we find that fluorescence from Topaz-tagged atrial natriuretic factor, a peptidergic vesicle pH indi

69 LV fibrosis, and expression of fetal genes (atrial natriuretic factor, alpha-skeletal muscle actin,

70 cardiac expression of HF marker genes (GRK2, atrial natriuretic factor, and beta-myosin heavy chain).

71 yosin heavy chain, cardiac troponin I and T, atrial natriuretic factor, and cardiac transcription fac

72 RNA expression of brain natriuretic peptide, atrial natriuretic factor, and renin were significantly

73 pregulation of hypertrophy markers including atrial natriuretic factor, beta-MHC, and GATA4; and acti

74 onic and contractile protein genes including atrial natriuretic factor, beta-myosin heavy chain, and

75 expression of the hypertrophic marker genes, atrial natriuretic factor, brain natriuretic peptide, an

76 pressed genes including cardiac alpha actin, atrial natriuretic factor, cardiac myosin heavy chain al

77 o well-known markers of cardiac hypertrophy (atrial natriuretic factor, CARP, and beta-myosin heavy c

78 n reaction, we measured transcript levels of atrial natriuretic factor, myosin heavy chain-alpha and

79 hy like: alpha- and beta-myosin heavy chain, atrial natriuretic factor, phospholamban, and sarcoplasm

80 However, in vivo imaging of a neuropeptide, atrial natriuretic factor, tagged with green fluorescent

81 Expression of fetal-type genes, such as atrial natriuretic factor, was also significantly lower

82 ytosis were developed by expressing a prepro-atrial natriuretic factor-green fluorescent protein fusi

83 iferase gene expression but no activation of atrial natriuretic factor-luciferase gene expression.

84 onomous accumulation of the endocytic tracer atrial natriuretic factor-red fluorescent protein at ear

85 Atrial natriuretic factor-VEGF-B167 expression was low i

86 osin heavy chain, myosin light chain 2v, and atrial natriuretic factor.

87 nduction of fetal genes such as betaMyHC and atrial natriuretic factor.

88 d expression of the hypertrophic marker gene atrial natriuretic factor.

89 ricles expressed beta-myosin heavy chain and atrial natriuretic factor.

90 y reduced ET-1- and PE-induced expression of atrial natriuretic factor.

91 lmonary congestion and had reduced levels of atrial natriuretic factor.

92 r greater, P=0.001), had increased levels of atrial natriuretic peptide (7.3 versus 4.9 pmol/L, P=0.0

93 Atrial natriuretic peptide (ANP) acts acutely to reduce

94 the EGR1-regulated cardioprotective peptides atrial natriuretic peptide (ANP) and B-type natriuretic

95 Cardiomyocytes secrete atrial natriuretic peptide (ANP) and B-type natriuretic

96 The cardiac natriuretic peptides (NPs), atrial natriuretic peptide (ANP) and B-type natriuretic

97 of circulating cardiac natriuretic peptides, atrial natriuretic peptide (ANP) and B-type or brain nat

98 Atrial natriuretic peptide (ANP) and brain natriuretic p

99 ctivation of a fetal gene program, including atrial natriuretic peptide (ANP) and brain natriuretic p

100 at baseline, messenger ribonucleic acid for atrial natriuretic peptide (ANP) and brain natriuretic p

101 referred to as atrial natriuretic factor or atrial natriuretic peptide (ANP) and brain or B-type nat

102 ct (IMCD) cells contributes to resistance to atrial natriuretic peptide (ANP) and the excessive sodiu

103 Subnanomolar concentrations of atrial natriuretic peptide (ANP) and type C natriuretic

104 he natriuretic signaling pathway in RPE with atrial natriuretic peptide (ANP) and with membrane-perme

105 Atrial natriuretic peptide (ANP) binding sites have been

106 After atrial natriuretic peptide (ANP) binding to NPRA, ligand

107 Atrial natriuretic peptide (ANP) binds guanylyl cyclase-

108 Atrial natriuretic peptide (ANP) binds guanylyl cyclase-

109 in natriuretic peptide A (NPPA) encoding the atrial natriuretic peptide (ANP) causes inflammation, fi

110 Effects of sacubitril/valsartan on atrial natriuretic peptide (ANP) concentrations in patie

111 Corin is a recently discovered pro-atrial natriuretic peptide (ANP) convertase that is abun

112 cardiac serine protease that acts as the pro-atrial natriuretic peptide (ANP) convertase.

113 Circulating natriuretic peptides such as atrial natriuretic peptide (ANP) counterbalance the effe

114 ibited hypertrophy concurrent with increased atrial natriuretic peptide (ANP) expression that depende

115 mice, TAC resulted in a 15-fold increase in atrial natriuretic peptide (ANP) expression, a 55% incre

116 with Src, modulated basal and ET-stimulated atrial natriuretic peptide (ANP) gene promoter activity,

117 tudy was to investigate the impact of rs5065 atrial natriuretic peptide (ANP) gene variant on coronar

118 ciated with rs5068, a genetic variant of the atrial natriuretic peptide (ANP) gene.

119 mulated contractility, whereas 10 micromol/L atrial natriuretic peptide (ANP) had no effect.

120 Atrial natriuretic peptide (ANP) has a central role in r

121 The role of atrial natriuretic peptide (ANP) in regulating fetal car

122 e main receptor that mediates the effects of atrial natriuretic peptide (ANP) in the regulation of pl

123 assess the dynamics of nitric oxide (NO) and atrial natriuretic peptide (ANP) induced synthesis of in

124 Atrial natriuretic peptide (ANP) influences glucose home

125 Atrial natriuretic peptide (ANP) inhibited VPF signaling

126 The cardiac hormone atrial natriuretic peptide (ANP) is a 28-amino acid (AA)

127 Atrial natriuretic peptide (ANP) is a cardiac hormone th

128 Atrial natriuretic peptide (ANP) is a hormone with diure

129 Atrial natriuretic peptide (ANP) is a hormone with numer

130 Atrial natriuretic peptide (ANP) is a peptide hormone th

131 Atrial natriuretic peptide (ANP) is an endogenous peptid

132 Although atrial natriuretic peptide (ANP) is not amidated, Pam ex

133 of this study was to examine the effects of atrial natriuretic peptide (ANP) on cytosolic Ca2+ oscil

134 intravital microscopy to study the effect of atrial natriuretic peptide (ANP) on the extrasplenic mic

135 the major and possibly the only receptor for atrial natriuretic peptide (ANP) or B-type natriuretic p

136 Cyclic GMP (cGMP) made in response to atrial natriuretic peptide (ANP) or nitric oxide (NO) is

137 orskolin), we found that low doses of either atrial natriuretic peptide (ANP) or NO donors potentiate

138 extracellular hormone binding domain of the atrial natriuretic peptide (ANP) receptor contains two p

139 The most studied member is the atrial natriuretic peptide (ANP) receptor, which is invo

140 y and guanylyl cyclase catalytic) domains of atrial natriuretic peptide (ANP) receptor-A (Npra) in po

141 st that oxytocin may mediate stretch-induced atrial natriuretic peptide (ANP) secretion.

142 ism for antiapoptotic signaling initiated by atrial natriuretic peptide (ANP) stimulation leading to

143 ier would attenuate the action of endogenous atrial natriuretic peptide (ANP) to increase vascular pe

144 Atrial natriuretic peptide (ANP) via its guanylyl cyclas

145 Circulating chimeric atrial natriuretic peptide (ANP) was detected in high co

146 ive partition analysis indicated that (125)I-atrial natriuretic peptide (ANP) was rapidly released in

147 12-amino acid extension to the C terminus of atrial natriuretic peptide (ANP) was recently geneticall

148 enzyme) is a cardiac protease that activates atrial natriuretic peptide (ANP), a cardiac hormone that

149 nd treat systemic hypertension by expressing atrial natriuretic peptide (ANP), a hormone able to decr

150 RP17 in cardiomyocytes enhances secretion of atrial natriuretic peptide (ANP), a regulator of blood p

151 al structures of the complexes of NPR-C with atrial natriuretic peptide (ANP), and with brain natriur

152 Concentrations of atrial natriuretic peptide (ANP), brain natriuretic pept

153 translated region of NPPA, the gene encoding atrial natriuretic peptide (ANP), is associated with blo

154 blood pressure and fluid homeostasis by the atrial natriuretic peptide (ANP), making PDE2-type enzym

155 The receptor for atrial natriuretic peptide (ANP), natriuretic peptide re

156 A cardiac hormone, atrial natriuretic peptide (ANP), plays a major role in

157 pro-atrial natriuretic peptide (pro-ANP) to atrial natriuretic peptide (ANP), suggesting that corin

158 ases in vascular permeability in response to atrial natriuretic peptide (ANP), which acts with the ki

159 GC) activity of the receptor protein in both atrial natriuretic peptide (ANP)-dependent and -independ

160 Nitric oxide (NO)- and atrial natriuretic peptide (ANP)-initiated cGMP signalin

161 exin A6 (Anxa6) to be a crucial regulator of atrial natriuretic peptide (ANP)-mediated counterhypertr

162 component of the intracellular modulation of atrial natriuretic peptide (ANP)-stimulated activation o

163 an endogenous receptor guanylate cyclase for atrial natriuretic peptide (ANP).

164 production of vasodilatory peptides, such as atrial natriuretic peptide (ANP).

165 uanylate cyclase that acts as a receptor for atrial natriuretic peptide (ANP).

166 ular leak can be prevented by treatment with atrial natriuretic peptide (ANP).

167 ATA4) that encodes a transcription factor of atrial natriuretic peptide (ANP).

168 udy tested the hypothesis that activation of atrial natriuretic peptide (ANP)/cGMP/protein kinase G s

169 ngiotensin II (ANG II; vasoconstrictive) and atrial natriuretic peptide (ANP; vasodilatory) antagoniz

170 Synthetic atrial natriuretic peptide (carperitide) and B-type natr

171 potential therapeutic applications of mutant atrial natriuretic peptide (mANP).

172 s the diagnostic utility of mid-regional pro-atrial natriuretic peptide (MR-proANP) for the diagnosis

173 enomedullin (MR-proADM), and midregional pro-atrial natriuretic peptide (MR-proANP) in a large prospe

174 sess the prognostic value of midregional pro-atrial natriuretic peptide (MR-proANP) in patients after

175 4 cardiovascular biomarkers, midregional pro-atrial natriuretic peptide (MR-proANP), midregional pro-

176 n AMI is the increased cardiac expression of atrial natriuretic peptide (NP) and B-type NP, with thei

177 th increased plasma levels of N-terminal pro-atrial natriuretic peptide (p = 0.002), after adjustment

178 in men, P<0.001 in women) and N-terminal pro-atrial natriuretic peptide (P<0.001 in men, P=0.001 in w

179 93 cells, we showed that corin converted pro-atrial natriuretic peptide (pro-ANP) to atrial natriuret

180 In cell-based studies, corin converted pro-atrial natriuretic peptide (pro-ANP) to mature ANP, sugg

181 C resulted in marked increases of myocardial atrial natriuretic peptide 4-hydroxy-2-nonenal (a marker

182 gical domains: neurohormonal (N-terminal pro-atrial natriuretic peptide [N-ANP], B-type natriuretic p

183 ohumoral factors, cytokines, endothelin, and atrial natriuretic peptide all may participate in HPA ax

184 Atrial natriuretic peptide also prevented stimulation of

185 Brain natriuretic peptide and atrial natriuretic peptide also released norepinephrine

186 ion of the fetal gene program (ie, increased atrial natriuretic peptide and alpha skeletal actin gene

187 s less hypotensive than the cardiac peptides atrial natriuretic peptide and B-type natriuretic peptid

188 for age and clinical covariates, N-terminal atrial natriuretic peptide and B-type natriuretic peptid

189 In men, N-terminal atrial natriuretic peptide and B-type natriuretic peptid

190 rdiovascular regulator that is stimulated by atrial natriuretic peptide and B-type natriuretic peptid

191 ions of natriuretic peptides (N-terminal pro-atrial natriuretic peptide and B-type natriuretic peptid

192 eased expression of cardiac embryonic genes (atrial natriuretic peptide and beta-myosin heavy chain)

193 logical properties with the cardiac hormones atrial natriuretic peptide and brain natriuretic peptide

194 NPR)-A is the primary signaling receptor for atrial natriuretic peptide and brain natriuretic peptide

195 In competition binding experiments, atrial natriuretic peptide and brain type natriuretic pe

196 ated the TAC-induced increases of myocardial atrial natriuretic peptide and the oxidative stress mark

197 Moreover, while levels of mRNA encoding atrial natriuretic peptide are reduced in E17.5 GR(-/-)

198 contribute) is the key process through which atrial natriuretic peptide attenuates elevations in cyto

199 ales, cardiac expression of the precursor of atrial natriuretic peptide B and of adrenomedullin also

200 neuropeptides gastrin-releasing peptide and atrial natriuretic peptide B in the spinal cord.

201 The cardiac serine protease corin is the pro-atrial natriuretic peptide convertase.

202 We show that atrial natriuretic peptide does not modulate the release

203 ressed in mice revealed that this unexpected atrial natriuretic peptide effect is brought about by sp

204 iogenesis, increased Akt activity, decreased atrial natriuretic peptide gene expression, and maintena

205 ntricular myocytes, with increased secretory atrial natriuretic peptide granules and degenerative mye

206 ns, the most intriguing have been the use of atrial natriuretic peptide in patients with nonoliguric

207 mm(2), P < 0.01) and marker gene expression (atrial natriuretic peptide increased by 409 +/- 32%, and

208 Finally, we revealed that atrial natriuretic peptide increased phosphorylation of

209 lls, both the NO donor S-nitrosocysteine and atrial natriuretic peptide induced SSG1 phosphorylation,

210 xpressed in cardiomyocytes that converts pro-atrial natriuretic peptide into atrial natriuretic pepti

211 Atrial natriuretic peptide is a circulating hormone that

212 Midregional pro-atrial natriuretic peptide is a newly described stable f

213 Midregional pro-atrial natriuretic peptide is a powerful predictor of ad

214 rdiomyocytes expression of the stress-marker atrial natriuretic peptide is suppressed by EMD 57033.

215 .05) while concurrently reducing circulating atrial natriuretic peptide levels (p < 0.01).

216 Midregional pro-atrial natriuretic peptide may represent a clinically us

217 ulate the reduced fat oxidation and elevated atrial natriuretic peptide message of cardiac hypertroph

218 of this study was to examine the effects of atrial natriuretic peptide on potentially harmful elevat

219 one (NT-pro-BNP), and N-terminal fragment of atrial natriuretic peptide pro-hormone (NT-pro-ANP) leve

220 e hypertension, and corin activation and pro-atrial natriuretic peptide processing activity were unde

221 ented corin activation and inhibited its pro-atrial natriuretic peptide processing activity.

222 hese pathways, related to the stimulation of atrial natriuretic peptide production and secretion.

223 iously undiscovered, mechanism through which atrial natriuretic peptide protects rat hepatocytes, and

224 tic peptide receptor 1 gene, encoding NPR-A, atrial natriuretic peptide receptor 1) was recently show

225 two categorically different models (lack of atrial natriuretic peptide receptor A; overexpression of

226 talized in myocytes, as it was distinct from atrial natriuretic peptide receptor-cGMP-PKG-RyR2 Ser-28

227 The atrial natriuretic peptide secreted by atrial myocytes i

228 It converts pro-atrial natriuretic peptide to atrial natriuretic peptide

229 -type natriuretic peptide and N-terminal pro-atrial natriuretic peptide to the risk of death from any

230 Atrial natriuretic peptide together with PDE9a inhibitor

231 e was 24% lower (P<0.001) and N-terminal pro-atrial natriuretic peptide was 16% lower (P<0.001); in w

232 e was 29% lower (P<0.001) and N-terminal pro-atrial natriuretic peptide was 18% lower (P<0.001).

233 Atrial natriuretic peptide was found to be up-regulated

234 ncluded vasoactive peptides; the vasodilator atrial natriuretic peptide was induced by CSD, while the

235 - or 12-week-old animals, and the PCH marker atrial natriuretic peptide was not different in young ve

236 s, extracellular matrix (ECM), integrin, and atrial natriuretic peptide were assessed.

237 -type natriuretic peptide and N-terminal pro-atrial natriuretic peptide with metabolic risk factors,

238 estry, and identified associations of plasma atrial natriuretic peptide with rs5068 (P = 8 x 10(-70))

239 ANP (atrial natriuretic peptide) and BNP (B-type natriuretic

240 he expression of known hypertrophic markers (atrial natriuretic peptide) and transcription factor act

241 etic peptides (C-type natriuretic peptide >> atrial natriuretic peptide) and, to a much smaller exten

242 ells expressed middle neurofilament (but not atrial natriuretic peptide) mRNA and protein.

243 gic hypertrophy (beta-myosin heavy chain and atrial natriuretic peptide) was measured with a quantita

244 s-sectional area, and the expression of ANP (atrial natriuretic peptide) were significantly attenuate

245 n-1, CT-pro-arginine vasopressin, and MR-pro-atrial natriuretic peptide), alone or as a panel, could

246 all thickness, increased lung levels of ANP (atrial natriuretic peptide), BNP (brain-type natriuretic

247 ic* and pulmonary* vascular resistances, and atrial natriuretic peptide*.

248 t converts pro-atrial natriuretic peptide to atrial natriuretic peptide, a cardiac hormone that regul

249 converts pro-atrial natriuretic peptide into atrial natriuretic peptide, a cardiac hormone that regul

250 n plasma adrenomedullin, with higher urinary atrial natriuretic peptide, adrenomedullin, and cGMP exc

251 , B-type natriuretic peptide, N-terminal pro-atrial natriuretic peptide, aldosterone, renin, fibrinog

252 ) of cardiac-specific genes (Nkx2.5, GATA-4, atrial natriuretic peptide, alpha- and beta-myosin heavy

253 leation, molecular up-regulation of released atrial natriuretic peptide, altered expression of classi

254 nosine reduced cell area, protein synthesis, atrial natriuretic peptide, and 3'-nitrotyrosine.

255 ion, LVEF, serum ACE, plasma angiotensin II, atrial natriuretic peptide, and brain natriuretic peptid

256 m salt (DEA/NO) or the natriuretic peptides, atrial natriuretic peptide, and C-type natriuretic pepti

257 itivities of their cGMP responses to DEA/NO, atrial natriuretic peptide, and C-type natriuretic pepti

258 rations for histology, middle neurofilament, atrial natriuretic peptide, and connexin (Cx) 43 reveale

259 agents at this time appear to be adenosine, atrial natriuretic peptide, and cyclosporine, with other

260 ulate whereas somatostatin, cholecystokinin, atrial natriuretic peptide, and nitric oxide inhibit aci

261 ene-related peptide, adrenomedullin, amylin, atrial natriuretic peptide, and pituitary adenylate cycl

262 mic arteries with substance P, epoprostenol, atrial natriuretic peptide, and relaxin (concentration r

263 for reduced fat oxidation to affect cardiac atrial natriuretic peptide, and thus, induce adipose lip

264 l, carbonyls), hypertrophic gene expression (atrial natriuretic peptide, B-type natriuretic peptide,

265 assessed the relations of plasma N-terminal atrial natriuretic peptide, B-type natriuretic peptide,

266 tricular expressions of the genes coding for atrial natriuretic peptide, beta myosin heavy chain, med

267 g expression of the hypertrophy gene markers atrial natriuretic peptide, brain natriuretic peptide, b

268 Phase 2 began with de Bold's discovery of atrial natriuretic peptide, followed by isolation of the

269 rprisingly, L-CPT1 hearts contained elevated atrial natriuretic peptide, indicating induction of hype

270 odilatin, the renally synthesized isoform of atrial natriuretic peptide, may improve pulmonary conges

271 action of numerous other regulators such as atrial natriuretic peptide, neurotensin, and orexin B ar

272 n effect further enhanced in the presence of atrial natriuretic peptide, NO, and treprostinil.

273 gregate (amylin, ACTH, LHRH, angiotensin II, atrial natriuretic peptide, somatostatin, oxytocin, neur

274 3T3 cells was increased by prior exposure to atrial natriuretic peptide, suggesting that hormone bind

275 We show that atrial natriuretic peptide, through protein kinase G, at

276 the approximately 180-kDa fragment activated atrial natriuretic peptide, whereas the approximately 16

277 However, the atrial natriuretic peptide, which is induced during left

278 mplants to produce sufficient amounts of the atrial natriuretic peptide, which reduced the blood pres

279 lective PDE2 inhibitor BAY 60-7550 augmented atrial natriuretic peptide- and treprostinil-evoked pulm

280 Corin (also known as atrial natriuretic peptide-converting enzyme) is a cardi

281 This report implicates perturbation of the atrial natriuretic peptide-cyclic guanosine monophosphat

282 g both the renin-angiotensin-aldosterone and atrial natriuretic peptide-degrading systems simultaneou

283 f rats with RO-25-6760 for 7 d increased the atrial natriuretic peptide-dependent excretion of sodium

284 PDE5 inhibition did not alter atrial natriuretic peptide-stimulated cGMP in the restin

285 the NEP-dependent degradation of vasodilator atrial natriuretic peptide.

286 ous frameshift mutation in the gene encoding atrial natriuretic peptide.

287 c protease responsible for the activation of atrial natriuretic peptide.

288 described stable fragment of N-terminal pro-atrial natriuretic peptide.

289 tion of the cardiac-derived peptide hormone, atrial natriuretic peptide.

290 that degrades vasoactive peptides, including atrial natriuretic peptide.

291 lar results were obtained for N-terminal pro-atrial natriuretic peptide.

292 sue weight assessment and gene expression of atrial natriuretic peptide.

293 All patients showed low serum levels of atrial natriuretic peptide.

294 re healthy and demonstrated normal levels of atrial natriuretic peptide.

295 r function, and severely decreased levels of atrial natriuretic peptide.

296 cant even after adjusting for N-terminal pro-atrial natriuretic peptide.

297 or-stimulated cardiomyocyte contractility by atrial natriuretic peptide/cGMP signaling in early cardi

298 y overcoming the resistance to diuretics and atrial-natriuretic-peptide and inhibiting Na-H exchanger

299 lamines, renin, aldosterone, angiotensin and atrial natriuretic peptides (ANP, N-ANP and BNP) were me

300 The NPPA gene codes for the precursor of atrial natriuretic polypeptide, suggesting that NPPA may